Researchers have taken an important step toward solving one of the biggest challenges in gene therapy for children with ...

Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose ...

U.S. Rare Disease Genome Editing Market to Reach USD 3.60 Billion and Europe USD 3.42 Billion by 2035 as CRISPR Adoption, ...

Beam Therapeutics (BEAM) stock slips on updated data from a Phase 1/2 trial for BEAM-302, its gene-editing drug for alpha-1 ...

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...

A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using ...

Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

Strengthened laws should help to ensure future deaths are quickly disclosed to the public, but China’s reputation for such ...

Vylor, Corteva's new entity, aims to establish a gene-editing hub in Hyderabad, maintaining a $1 billion R&D budget.

The study's lead author told Newsweek that gene editing could become another tool for addressing health problems in dogs.